• Founder(s): Prof. Dr. Dirk Jäger and Prof Dr. Jürgen Krauss
  • Established: 2016
  • CEO(s): Dr. Michaela Arndt
  • Employees: 5
  • Financial Data: Privately funded 
  • Website: N/A


This company is translating innovative science into successful immunotherapeutic approaches.

Heidelberg ImmunoTherapeutics is a clinical stage company dedicated to the clinical development of innovative immunotherapeutics for viral diseases and cancer. Their current clinical lead compound is a humanized monoclonal antibody for the treatment of human herpes simplex virus (HSV) infections and represents a milestone in their continued effort to move a pipeline of novel and innovative immunopharmaceuticals into clinical applications in areas of significant medical need.

Heidelberg ImmunoTherapeutics has access to three top-tier preclinical as well as clinical infrastructures, the German Cancer Research Center (DKFZ), the Heidelberg University Hospital and the National Center for Tumor Diseases (NCT). The NCT stands for a high standard of clinical patient care in combination with ongoing cancer research. To succeed in the clinical development of proprietary immunotherapeutic compounds, Heidelberg ImmunoTherapeutics highly benefits from NCT’s knowledge for developing and conducting early clinical trials (both IIT and industry-sponsored) with a special emphasis on immunotherapy studies that include sophisticated correlative research programs.